Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
CJC-1295 (with DAC) (CJC-DAC) is a growth hormone peptide, at the clinical trials stage in the published literature. CJC-1295 with Drug Affinity Complex that extends half-life dramatically, providing sustained GH elevation over days rather than hours.
CJC-1295 with Drug Affinity Complex that extends half-life dramatically, providing sustained GH elevation over days rather than hours.
| Research Status | Clinical trials |
|---|---|
| Half-Life | 6-8 days |
| Administration | Subcutaneous injection |
| Doses Reported in Published Studies | 1-2 mg per week |
GHRH analog with DAC modification allowing albumin binding, creating depot effect for prolonged GH release.
CJC-1295 with Drug Affinity Complex that extends half-life dramatically, providing sustained GH elevation over days rather than hours.
GHRH analog with DAC modification allowing albumin binding, creating depot effect for prolonged GH release.
CJC-1295 (with DAC) is at the following stage in the published literature: Clinical trials. All information is for research and educational purposes only.
Reported half-life: 6-8 days.
Reported administration route in the literature: Subcutaneous injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.